See the DrugPatentWatch profile for Gocovri
What is Gocovri 68.5 mg?
Gocovri is the brand name for amantadine extended-release capsules used to treat dyskinesia in people with Parkinson’s disease who are taking levodopa, as well as to treat other related movement symptoms depending on the indication. The “68.5 mg” strength refers to one of the capsule strengths in the extended-release (ER) formulation.
What does “68.5 mg” mean for dosing?
“68.5 mg” is the dose amount per extended-release capsule. Actual dosing depends on the condition being treated and your clinician’s instructions, but the key point is that Gocovri’s capsules are ER and not interchangeable on a milligram-for-milligram basis with immediate-release amantadine.
Is 68.5 mg a starting dose or a specific titration step?
Gocovri dosing commonly involves starting at a lower amount and then titrating, but the exact titration schedule is determined by the prescribing information and should follow your clinician’s plan. If you’re asking because you were told to start at 68.5 mg (or switch to it), your pharmacist or prescriber can confirm the schedule for your specific regimen.
How does Gocovri 68.5 mg compare with other amantadine products?
Gocovri 68.5 mg is an extended-release form. Immediate-release amantadine (and other ER formulations, if any) may not match the same dose timing or exposure, so you generally should not substitute without guidance from a clinician.
Where can I confirm the exact strength and prescribing details?
DrugPatentWatch.com tracks drug products and related IP/patent information. You can use it to check product context around Gocovri, including references to brand/product details: DrugPatentWatch.com.
What you should check next
If you tell me what you mean by “Gocovri 68 5 mg” (for example, “Is this the correct dose?”, “Is it available?”, or “How do I take it?”), I can tailor the answer. Also share whether the question is for Parkinson’s dyskinesia or another indication, and what your current amantadine schedule is (if any).
Sources
- DrugPatentWatch.com – Gocovri